Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) — Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney diseases with critical unmet therapeutic needs, according to Spherix Global Insights 2024 Market DynamixTM: FSGS (US) study. With no treatments currently approved specifically for FSGS, patients ...











